Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities

Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and... BackgroundPsoriasis severity has traditionally been categorized as mild, moderate, and severe. Commonly, cut-offs for severe disease require a body surface area (BSA) involvement of ≥10% or a Psoriasis Area Severity Index (PASI) > 10. However, clinical experience challenges these traditional measures and requirements, as patients with less extensive psoriasis may have disease that severely impacts quality of life.ObjectiveThe objective of the present study was to further explore the extent of patient burden when psoriasis affects special locations.MethodsA total of 69,190 individuals living in the U.S were invited to participate in a patient advocacy survey by telephone and or web interviews over the course of 3 years (2019-2021). The survey instrument consisted of validated patient-reported outcome measures, measuring disease-specific quality of life (Dermatology Life Quality Index, DLQI), depression (Patient Health Questionnaire (PHQ)-2 and (PHQ)-9), and the ability to participate in social roles and activities (PROMIS Ability to Participate in Social Roles and Activities (SF-4a). Chi-square tests were performed to explore association between psoriasis involvement on special locations and patient outcomes and multivariate logistic regression models were then constructed, to assess impact of having psoriasis on special locations patient outcomes, controlling for potential confounding factors.ResultsA total of 4129 individuals completed the survey. 3594 (84.4%) of patients surveyed reported psoriasis involving special areas of the bodysuch as the scalp, face, hands, feet, or genitalia. Involvement of special areas is associated with worse quality of life and depression. 35-71% of patients with 10% or less total BSA involvement experienced a moderate-to-extremely large effect on these life function domains. When adjusting for age, sex, and body surface area, psoriasis involvement of a special location was associated with poorer patient reported outcomes, including a 46% less likelihood of reporting their skin disease as having “no or only a small effect on QoL,” a 30% less likelihood of having a “normal l ability to participate in social roles and activities,” and a 126% higher likelihood of f having depression.ConclusionReal-world data presented here demonstrate that psoriasis involving special areas is associated with adverse life consequences, including poor quality of life and depression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Psoriasis and Psoriatic Arthritis SAGE

Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities

Download PDF
7 pages

Loading next page...
 
/lp/sage/psoriasis-involving-special-areas-is-associated-with-worse-quality-of-PLHlyAVHF9
Publisher
SAGE
Copyright
© The Author(s) 2023
ISSN
2475-5303
eISSN
2475-5311
DOI
10.1177/24755303231160683
Publisher site
See Article on Publisher Site

Abstract

BackgroundPsoriasis severity has traditionally been categorized as mild, moderate, and severe. Commonly, cut-offs for severe disease require a body surface area (BSA) involvement of ≥10% or a Psoriasis Area Severity Index (PASI) > 10. However, clinical experience challenges these traditional measures and requirements, as patients with less extensive psoriasis may have disease that severely impacts quality of life.ObjectiveThe objective of the present study was to further explore the extent of patient burden when psoriasis affects special locations.MethodsA total of 69,190 individuals living in the U.S were invited to participate in a patient advocacy survey by telephone and or web interviews over the course of 3 years (2019-2021). The survey instrument consisted of validated patient-reported outcome measures, measuring disease-specific quality of life (Dermatology Life Quality Index, DLQI), depression (Patient Health Questionnaire (PHQ)-2 and (PHQ)-9), and the ability to participate in social roles and activities (PROMIS Ability to Participate in Social Roles and Activities (SF-4a). Chi-square tests were performed to explore association between psoriasis involvement on special locations and patient outcomes and multivariate logistic regression models were then constructed, to assess impact of having psoriasis on special locations patient outcomes, controlling for potential confounding factors.ResultsA total of 4129 individuals completed the survey. 3594 (84.4%) of patients surveyed reported psoriasis involving special areas of the bodysuch as the scalp, face, hands, feet, or genitalia. Involvement of special areas is associated with worse quality of life and depression. 35-71% of patients with 10% or less total BSA involvement experienced a moderate-to-extremely large effect on these life function domains. When adjusting for age, sex, and body surface area, psoriasis involvement of a special location was associated with poorer patient reported outcomes, including a 46% less likelihood of reporting their skin disease as having “no or only a small effect on QoL,” a 30% less likelihood of having a “normal l ability to participate in social roles and activities,” and a 126% higher likelihood of f having depression.ConclusionReal-world data presented here demonstrate that psoriasis involving special areas is associated with adverse life consequences, including poor quality of life and depression.

Journal

Journal of Psoriasis and Psoriatic Arthritis – SAGE

Published: Jul 1, 2023

Keywords: psoriasis; disease severity; mental health; quality of life; treatment

References

  • Current severe psoriasis and the rule of tens
    Finlay, AY
  • Psoriasis and the risk of diabetes: A prospective population-based cohort study
    Wan, MT; Shin, DB; Hubbard, RA; Noe, MH; Mehta, NN; Gelfand, JM
  • Objective measures of psoriasis severity predict mortality: A prospective population-based cohort study
    Noe, MH; Shin, DB; Wan, MT; Gelfand, JM
  • Body surface area affected by psoriasis and the risk for psoriatic arthritis: A prospective population-based cohort study
    Ogdie, A; Shin, DB; Love, TJ; Gelfand, JM
  • Psoriasis severity: Commonly used clinical thresholds may not adequately convey patient impact
    Golbari, NM; van der Walt, JM; Blauvelt, A; Ryan, C; van de Kerkhof, P; Kimball, AB
  • Recategorization of psoriasis severity: Delphi consensus from the international psoriasis council
    Strober, B; Ryan, C; van de Kerkhof, P; van der Walt, J; Kimball, AB; Barker, J
  • Efficacy and safety of ixekizumab in a randomized, double blinded placebo controlled phase IIIb study of patients with moderate to severe genital psoriasis
    Ryan, C; Menter, A; Guenther, L
  • Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails
    Merola, JF; Qureshi, A; Husni, ME
  • Is facial involvement a sign of severe psoriasis?
    Canpolat, F; Cemil, BC; Eskioğlu, F; Akis, HK
  • Prevalence of psoriasis phenotypes among men and women in the USA
    Merola, JF; Li, T; Li, WQ; Cho, E; Qureshi, AA
  • Genital psoriasis is associated with significant impairment in quality of life and sexual functioning
    Ryan, C; Sadlier, M; De Vol, E
  • Quality of life and sexual health in patients with genital psoriasis
    Meeuwis, KAP; de Hullu, JA; van de Nieuwenhof, HP
  • Griffiths CEM psoriasis prevalence in adults in the United States
    Armstrong, AW; Mehta, MD; Schupp, CW; Gondo, GC; Bell, SJ
  • The Patient Health Questionnaire- 2: Validity of a two-item depression screener
    Kroenke, K; Spitzer, RL; Williams, JBW